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Abstract. The purpose of this study was to investigate the
molecular biological characteristics of malignant mucosal
melanoma (MMM) and adenoid cystic carcinoma (ACC)
of the head and neck. We analyzed the common genetic
abnormalities that may help to identify the loci in the genes
involved in the development of MMM and ACC of the head
and neck by PCR-LOH on chromosomes 1p, 6q, 9p, 10q,
11q, 12q, 17p, and 19q. LOH was observed in 6 of 12 cases
of MMM and in 12 of 15 cases of ACC informative for at
least one of the loci analyzed. One distinct deleted region
was identified at chromosome 9p21. In addition, to identify a
possible involvement of p16/CDKN2 PCR-SSCP and auto-
DNA sequence analysis were also performed to detect any
mutation of the p16/CDKN2. Particularly, 2 missense mutations
were detected in codon 225 and 226, both in MMM and
ACC. There were mutational hot spots in the p16/CDKN2
gene. These results suggested that mutation of the p16/CDKN2
gene was a common factor in the development of human
MMMs and ACCs, while this gene may be correlated with
development and/or progression of a subtype and play a role
in the oncogenesis of these cancers.
Introduction
Malignant mucosal melanoma (MMM) and adenoid cystic
carcinoma (ACC) are two of the malignant tumors with the
poorest prognosis. According to a previous report, the effective
treatment for these diseases is carbon ion radiotherapy using
heavy charged particles (1).
Clinical trials of carbon ion radiotherapy for various cancers
were initiated in June 1994 at the Hospital of the Research
Center for Charged Particle Therapy, National Institute of
Radiological Sciences (NIRS), using the world's first Heavy
Ion Medical Accelerator in Chiba (HIMAC) dedicated to
medical purposes (1). Preliminary results of phase II clinical
trials have shown extremely favorable therapeutic results in the
treatment of MMMs and ACCs that are otherwise intractable
with conventional photon radiation (2,3). As stated above,
radiotherapy with heavy charged particles is significantly
effective in the therapy of MMMs and ACCs of the head and
neck. Radiotherapy using the HIMAC has some characteristics
in common with conventional photon radiation. Firstly,
HIMAC irradiation inflicts fatal damage upon the DNA of
cancer cells so that cancer cell restoration is made difficult.
Secondly, HIMAC irradiation affects cells at any stage of the
cell cycle. Thirdly, the HIMAC irradiation has a cytocidal
effect on cancer cells also in a hypoxic environment. Lastly,
the distribution characteristics of HIMAC radiation are such
as to minimize damage to normal tissues while limiting
injury to the tumor only. However, no analysis method for
the molecular biological assessment of the effectiveness of
HIMAC radiation for MMMs and ACCs has yet been
established. We therefore considered that the molecular
biological characteristics such as loss of heterozygosity
(LOH) and microsatellite instability (MSI) may become
criteria for assessment of the effectiveness of HIMAC
radiotherapy for MMM and ACC prior to therapy. In recent
studies, LOH and MSI have been used for assessing allelic
imbalances. For example, allelic imbalances including LOH
and MSI in malignant cells have proven useful for mapping
DNA regions potentially harboring candidate tumor suppressor
genes (TSG). According to a previous study, a high incidence
of LOH has been detected in head and neck squamous cell
carcinomas (SCC) on several chromosome arms, including
2q, 3p, 4q, 5q, 7q, 8p, 9p, 10q, 11q, 13q, 18q, 20q, 21q, and
22q (4-7), where candidate TSGs may be present. 
We thus made a literature search to look for evidence of
prior gene analysis common to MMM and ACC, but the
extant literature does not provide any information on gene
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seat ranking common to both diseases. There were few
reports related to MMM, while most focused on cutaneos
melanoma (8). However, there was a significant number of
reports in the literature referring to gene analysis of ACC
(9,10). The limited number of loci tested and the varietal
incidence of genetic alterations in these studies make it
difficult to assess the regions of chromosomes 1p, 6q, 9p,
10q, 11q, 12q, 17p, and 19q (11-14) involved in cutaneos
melanoma and ACC of the head and neck. We paid particular
attention to the 3 chromosomes, 6p, 17p, and 9p. First, while
the chromosome region around 6p does not reveal a major
presence of a TSG it does show a high level of expression of
LOH in ACC and cutaneos melanoma. In contrast, the 17p
and 9p regions included the TSG p53 and p16. In particular,
p16/CDKN2 loci have been reported in previous studies that
have a high level of incidence of LOH in cutaneos melanoma
and ACC (10,15).
We therefore analyzed in this study, the molecular bio-
logical characteristics of MMM and ACC and identified the
p16/CDKN2 sequence.
Materials and methods
Tissue samples. Tissue samples were taken from 27 patients,
12 with MMMs and 15 with ACCs of the head and neck,
who attended the Hospital of the Research Center for Charged
Particle Therapy, NIRS, during the 2 years from 2002 through
2003 (Table I). Informed consent was obtained from all patients
and also from their families. In addition, this study was
approved by the institutional ethics committee in NIRS and
also by the Tokyo Dental College. Normal tissue specimens
as control were prepared from each patient's peripheral blood
samples at the time of biopsy. None of the tumors and normal
samples had undergone chemotherapy and radiotherapy prior
to biopsy. All tissues resected for biopsy were prepared using
a 10% formalin solution for pathologic diagnosis. Histopatho-
logic diagnosis was performed according to the International
Classification of Tumors (16).
All normal samples were prepared by immediate DNA
extraction by the method described below.
Tumor DNA extraction from paraffin sections and normal
DNA extraction from blood. Multiple 10-μm sections were
cut and mounted on silanated slides and left overnight at 37˚C.
They were then dewaxed with xylene and water with different
concentration levels of alcohol being successively added.
The sections were lightly stained in Harris hematoxylin and
compared with a hematoxylin and eosin-stained section on
the same block. All samples had histologically confirmed
MMM or ACC of the head and neck, and the tumor samples
for DNA extraction were checked by observing in biopsy to
ensure that they consisted of more than 80% tumor cells.
Genomic DNA was extracted from several paraffin-embedded
sections of all tumor samples using Takara DEXPAT® (Takara
Bio Inc, Shiga, Japan). A standard protocol of DEXPAT®
is shown below. Three 10-μm thick paraffin-embedded tissue
sections were prepared and placed in a microcentrifuge tube
using sterilized tweezers. Of a gently stirred DEXPAT solution,
0.5 ml per bottle was added to the centrifuging tube and mixed
with the sample to remove the resin. The microcentrifuge
tube was heated to and kept at 100˚C for 10 min in a block
heater and then centrifuged at 12,000 rpm for 10 min at 4˚C.
The thin paraffin layer was removed from the tube wall and the
supernatant was collected with a micropipette. After the DNA
samples had been extracted by phenol-chloroform extraction
and refined, they were washed and precipitated with ethanol.
The concentrations of extracted DNA were estimated by a
spectrophotometric method and the DNA samples were kept
at -80˚C.
Normal cells were prepared from peripheral blood samples
as control. The blood samples were used for analysis with the
Dr.GenTLE® (Takara Bio Inc) gene trapping kit. This kit is
composed of three solutions; GenTLE® solution I, II, and III.
GenTLE solution I lyses blood cells immediately after adding
it to the whole blood, and a non-charged complex with nucleic
acids is formed. The complex is collected by centrifugation,
and the DNA precipitates are washed with GenTLE solution
II. Then GenTLE solution III is added to isolate DNAs only,
and DNAs are precipitated by adding isopropanol. The
concentrations of the extracted DNA were estimated by a
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Table I. Summary of clinical features in 12 MMMs and 15
ACCs.
–––––––––––––––––––––––––––––––––––––––––––––––––
Sample no. Patient no. Location Age Gender
–––––––––––––––––––––––––––––––––––––––––––––––––
MMM
1 9 Palate 69 M
2 11 Nasal 77 M
3 17 Nasal 77 F
4 29 Nasal 78 M
5 48 Maxillary sinus 78 M
6 49 Nasal 77 F
7 52 Maxillary sinus 53 M
8 62 Maxillary sinus 52 M
9 66 Nasal 66 M
10 69 Palate 62 M
11 83 Ethmodial sinuses 55 F
12 89 Orbit 55 M
ACC
1 7 Sublingual gland 49 M
2 13 Parotid gland 58 F
3 27 Hard palate 44 M
4 30 Epipharynx 45 F
5 32 Maxillary sinus 49 M
6 54 Lacrimal gland 76 F
7 59 Maxillary sinus 64 M
8 64 Tongue 44 M
9 73 Epipharynx 26 F
10 75 Parotid gland 56 F
11 81 External acoustic meatus 50 F
12 86 Epipharynx 45 F
13 91 Parotid gland 52 F
14 96 Maxillary sinus 40 M
15 98 Maxillary sinus 37 F
–––––––––––––––––––––––––––––––––––––––––––––––––
MMM, malignant mucosal melanoma; ACC, adenoid cystic carcinoma; M, male;
F, female.
–––––––––––––––––––––––––––––––––––––––––––––––––
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spectrophotometric method and the DNA samples were kept
at -80˚C. From each DNA sample, 50 ng/μl was used for the
template of the PCR amplification procedure.
PCR and microsatellite analysis. We used 17 microsatellite
markers from among those on 1p32, 6q23-25, 9p21, 10q23-25,
11q23.3, 12q12-13, 17p13.1, and 19q13.1 (Table II). All
primers were obtained from Sigma-Aldrich Japan K.K.
(Hokkaido, Japan). The DNA fragments of the above DNA
sample were amplified with PCR in a 10-μl final volume
containing 0.25 units of HotStarTaq® DNA polymerase
(Qiagen GmbH, Hilden, Germany) in 10X PCR buffer (50 mM
KCL, 10 mM Tris-Cl, pH 8.0, 1.5 mM MgCl2), 0.2 mM
deoxynucleotide triphosphate, 0.2 μM of each primer, 2.5 mM
of MgCl2 and 2.5 ng genomic DNA. The amplification protocol
specifies initial denaturation for 15 min at 94˚C, 40 cycles of
20 sec each at 94˚C, 30 sec at 62˚C, 30 sec at 72˚C, followed
by a final extension step of 72˚C for 6 min according to the
protocol of Nakamoto et al (17). After dilution with an
adequate volume of formamide-dye mixture (95% formamide,
20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene
cyanol), the PCR products were heat-denatured (98˚C, 5 min),
chilled on ice, and electrophoresed on 6% urea-formamide-
polyacrylamide gel at 3 W for 2 h, depending on the fragment
size. Silver staining of the gels was performed using the DNA
silver staining kit (GE Healthcare UK Ltd, Buckinghamshire,
UK). To ensure reproducibility in each sample with LOH, all
tests were performed under the same conditions.
We carried out the previously described process twice to
confirm the reproducibility of the results.
Assessment of LOH and microsatellite instability (MSI).
LOH in the tumor DNA samples was assessed by scanning
densitometry and analyzed with NIH Image software (version
1.62, http://rsb.info.nih.gov/nih-image/). The intensities of
the signals from the tumor DNA were compared with those
of normal DNA as a control. The criterion for the presence of
LOH was a reduction in signal intensity of >50%. Commonly
deleted regions were defined by considering the loci most
frequently showing LOH, together with multiple interstitial
deletions. MSI in the DNA samples was assessed as positive
in cases with additional bands in the tumor sample that were
not observable in the normal samples and in cases showing a
band shift in the tumor sample that contrasted with the
pattern of the normal bands.
Detection of p16/CDKN2 gene alteration by PCR-SSCP and
auto-DNA sequence analysis. To screen the sequence variations
of the p16/CDKN2 gene, PCR-SSCP analysis was performed
as described previously (18,19). Four sets of oligonucleotide
primers as summarized in Table III were used to amplify the
entire coding region (exons 1 to 4) of the p16/CDKN2 gene.
Sequences for all annotated exons and adjacent intronic
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D1S160 F 5'-GCATCTAGCAAACAGCATGTG-3' 156
R 5'-GCTGGAGGGCAGTGAAACT-3'
D1S243 F 5'-CACACAGGCTCACATGCC-3' 209
R 5'-GCTCCAGCGTCATGGACT-3'
D9S104 F 5'-GATCTGGGTATGTCTTTCTG-3' 181
R 5'-ACTGGGACTCTAACTAATGT-3'
D6S310 F 5'-GATCCAGATTGCAGAAGG-3' 159
R 5'-GAAACAGGACCAGTAGGATAT G-3'
D9S736 F 5'-TTCTAGACCTCTCAGCAGAC-3' 157
R 5'-GATAGTGTTGGAGACACCAG-3'
D9S162 F 5'-GCAATGACCAGTTAAGGTTC-3' 181
R 5'-AATTCCCACAACAAATCTCC-3'
D9S171 F 5'-AGCTAAGTGAACCTCATCTCTGTCT-3' 159
R 5'-ACCCTAGCACTGATGGTATAGTCT-3'
D10S254 F 5'-ACTCCTTCCCATGTAGGTACC-3' 98
R 5'-TCCTGTTAAGATGTTACTGAG-3'
D11S29 F 5'-TCTAGCTCCACCATCCTGTG-3' 143
R 5'-ACAACACACTGCCACAAGAC-3'
TP53 F 5'-TTGCCTCTTTCCTAGCACTG-3' 103
R 5'-CCAAGACTTAGTACCTGAAG-3'
ACC
D6S310 F 5'-GATCCAGATTGCAGAAGG-3' 159
R 5'-GAAACAGGACCAGTAGGATATG-3'
D6S311 F 5'-ATGTCCTCATTGGTGTTGTG-3' 62
R 5'-GATTCAGAGCCCAGGAAGAT-3'
D6S441 F 5'-AACAATATTTGGTGACTGTTAAAGG-3' 103
R 5'-TGGACAAATTGATTAGGAAGTAAAG-3'
D9S171 F 5'-AGCTAAGTGAACCTCATCTCTGTCT-3' 159
R 5'-ACCCTAGCACTGATGGTATAGTCT-3'
D12S391 F 5'-AACAGGATCAATGGATGCAT-3' 135
R 5'-TATTGGACAGTAAAGAAACCTGC-3'
D12S1301 F 5'-ACACAGATGTGCATCTATCTCG-3' 132
R 5'-TATTGGACAGTAAAGAAACCTGC-3'
D12S1064 F 5'-AATATTGACTTTCTCTTGCTACC-3' 80
R 5'-ACTACTCCAAGGTTCCAGCC-3'
TP53 F 5'-TTGCCTCTTTCCTAGCACTG-3' 103
R 5'-CCAAGACTTAGTACCTGAAG-3'
D19S210 F 5'-TCACACTCACTGGTCTCTC -3' 57
R 5'-GGTGTGCCTGTGTGTAAAAG-3'
D19S246 F 5'-AGAGTGAGATTCCACCTTTC-3' 64
R 5'-GAAACACATCATTTACCCAC-3'
–––––––––––––––––––––––––––––––––––––––––––––––––





Exon 1 5'-GAAGAAAGAGGAGGGGTG-3' 340
5'-GCGCTACCTGATTCCAATTC-3'
Exon 2 5'-ACACAAGCTTCCTTTCCGTCAT-3' 426
5'-TCTGAGCTTTGGAAGCTCT-3'
Exon 3 5'-TTGATTATTTTGTTTTTTTTGGTAGGTT-3' 161
5'-CAAATTCTCAAATCATCAATCCTCACCT-3'
Exon 4 5'-AGGAATTCGGTAGGGACGGCAAGAGAGG-3' 215
5'-GAAGCTTGGGGGAAGGCATATATCTACG-3'
–––––––––––––––––––––––––––––––––––––––––––––––––
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sequences were extracted using the sequences made public
on the NCBI database (http://www.ncbi.nlm.nih.gov/). Primers
for PCR amplification and sequencing were designed using
the Primer 3 program (version 0.2, http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi). PCR was carried out in a
final volume of 25 μl of a reaction mixture containing 1X
LA-PCR buffer (Takara Bio Inc), 2 μM of each primer,
200 μM of each dNTP, 100 ng of template DNA, and 0.01
unit of LA-Taq DNA polymerase (Takara Bio Inc). Thirty-
five cycles of denaturation were performed at 94˚C for 10 sec
each, followed by annealing at 54˚C for 10 sec, and extension
at 72˚C for 30 sec. After amplification, the PCR products
were electrophoresed on 10% polyacrylamide gels under
different conditions at 4˚C, 15˚C, and room temperature.
After electrophoresis, the gel was silver-stained using a
DNA silver staining kit (GE Healthcare UK Ltd). Suspected
mutations were identified by re-amplification with the same
primer used in PCR-SSCP analysis, ligated into pCR2.1
vector (Invitrogen Japan K.K., Tokyo, Japan), and sequenced
on an Applied Biosystems 3730xl DNA analyzer (Applied
Biosystems Ltd, CA, USA).
Results
Analysis of LOH and MSI in MMM. We analyzed tumors
from 12 patients with MMM using PCR-LOH assay with 10
microsatellite markers. LOH was detected in six of 12 samples
(50.0%) in at least one region. The incidence of LOH for 10
microsatellite markers is shown in Table IV. The results of
the LOH analysis in tumor samples are shown in the deletion
map in Fig. 1. The highest incidence of LOH was found at the
marker D9S171 at 9p21 (33.3%). This locus has already been
reported as a candidate TSG locus for cutaneous melanoma
(20). The marker D9S171 has been mapped around the p16/
CDKN2 gene locus on 9p21 (21). 
Another frequently occurring LOH location was the marker
D6S310 at 6q23-25 (8.3%), D9S736 at 9p21 (8.3%), D9S162
at 9p21 (8.3%), and D11S29 at 11q23.3 (10.0%). In addition,
incidence of MSI was found at the microsatellite marker
D9S104 in sample no.8. For all of them, it was not possible
to assume a common deletion domain because expression
was ≤20%. 
Typical examples of LOH, informative (INF) and not
informative (NI) cases are shown in Fig. 2.
Analysis of LOH and MSI in ACC. The results of PCR-LOH
analysis of the tumor samples with LOH are shown in Fig. 1,
and Table IV. Fifteen tumor samples and normal tissues were
studied for LOH using 10 microsatellite markers. We detected
LOH in 80.0% (12/15) of the ACCs, the most frequently
deleted locus being D9S171 at 9p21. Of the 15 informative
cases, 8 (53.3%) showed LOH at D9S171. In the location of
D12S391, a frequency of LOH of 40% (6/15) was detected.
In addition, frequently detected loci were D6S310 at 6q23-25
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Figure 1. Deletion mapping of chromosomes 1p, 6q, 9p, 10q, 11q, and 17p
in 12 MMMs, and chromosomes 6q, 9p, 12q, 17p, and 19q in 15 ACCs.
Case numbers are shown at the top and locus symbols on the left.




Locus symbol LOH/informative cases Frequency of LOH (%) Locus symbol LOH/informative cases Frequency of LOH (%)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
D6S310 1/12 8.3 D6S310 1/15 6.7
D9S171 4/12 33.3 D9S171 8/15 53.3
TP53 0/10 0.0 TP53 0/8 0.0
D1S160 0/8 0.0 D6S441 0/15 0.0
D1S243 0/12 0.0 D6S311 0/13 0.0
D9S104 0/11 0.0 D12S391 6/15 40.0
D9S736 1/12 8.3 D12S1301 1/15 6.7
D9S162 1/12 8.3 D12S1064 0/14 0.0
D10S254 1/12 8.3 D19S210 1/15 6.7
D11S29 1/10 10.0 D19S246 1/14 7.1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
The former 3 markers are common to MMM and ACC; the remaining 7 markers are specific to each.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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(6.7%), D12S1301 at 12q12-13 (6.7%), D19S210 at 19q13.1
(6.7%), and D19S246 at 19q13.1 (7.1%). MSI was not found
in ACCs. Interestingly, a locus of D9S171 overlapped with
the proximal, commonly deleted region in MMM.
Typical examples of LOH, informative (INF) and not
informative (NI) cases are shown in Fig. 2.
SSCP and auto-sequencing of the p16/CDKN2 gene in MMM.
We investigated exons 1 to 4 of the p16/CDKN2 gene by
PCR-SSCP analysis in 12 primary tumors. We found mobility
shifts in 3 cases, sample nos. 4, 11, and 12, of the 8 cases
with LOH detected at D9S171 (30.0%) in exon 4 (Fig. 3),
and these bands were analyzed by automatic sequencer. In
tissue sample no. 4, 3 different nucleotide substitutions were
identified. These substitutions were from CCC to TCC at
codon 225, GAT to ATG at codon 226, and TGA to GTGA
(1-bp insertion) at codon 227, resulting in an amino acid
substitution, Pro to Ser, Asp to Met, and Stop to Val (Table V).
However, nucleotide substitutions were not detected in samples
no. 11 and 12.
SSCP and auto-sequencing of the p16/CDKN2 gene in ACC.
By PCR-SSCP analysis of exons 1 to 4 of the p16/CDKN2
gene, we identified mobility shifts in 8 of 15 cases (53.3%) in
exon 4 (Fig. 3). Auto-sequencer analysis was performed, on
sample no. 5, and 4 novel nucleotide substitutions at exon 4
were identified. These substitutions were from GAC to GAG
at codon 223, ATC to CAC at codon 224, CCC to AGG at
codon 225, and GAT to GAAT (1-bp insertion) at codon 226,
and resulted in an amino acid replacement from Asp to Glu,
Ile to His, Pro to Arg, and Asp to Glu (Fig. 4, Table V).
Sample no. 14 showed a frameshift mutation at codon 225
(CCC, 3-bp deletion) (Table V). While it was possible to
detect a band shift for sample nos. 3, 4, 7, 8, 11, and 15 (in
SSCP), investigation of the gene sequence using a sequencer
showed that no sequence abnormality or shift had occurred. 
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Figure 3. PCR-SSCP analysis for exon 4 of the p16/CDKN2A gene in MMMs
and ACCs. Case numbers are shown below each column. N, corresponding
normal tissue; T, tumor tissue.
Figure 2. Illustration of microsatellite polymorphism analysis in MMM and
ACC specimens. Case numbers are shown at the top, and locus symbols on
the left. Paired normal (N) and tumor (T) samples for patients 1, 6, 7, 8, and
12 demonstrating loss of the upper allele (LOH), retained heterozygosity
(INF) and not informative (NI), respectively.
Table V. Somatic mutations of the p16/CDKN2 gene in
MMMs and ACCs.
–––––––––––––––––––––––––––––––––––––––––––––––––
Case Base substitution Codon Amino-acid substitution
–––––––––––––––––––––––––––––––––––––––––––––––––
Sample no. 4 CCCTCC 225 ProSer
in MMMs GATATG 226 AspMet
TGAGTGA 227 StopVal (1-bp insertion)
Sample no. 5 GACGAG 223 AspGlu
in ACCs ATCCAC 224 IleHis
CCCAGG 225 ProArg
GATGAAT 226 AspGlu (1-bp insertion)
Sample no. 14 CCCdeletion 225 3-bp deletion
in ACCs
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 4. Sequencing analysis of the p16/CDKN2 gene. The 223rd codon
was changed from AC (Asp) to AG (Glu), the 224th codon was changed
from ATC (Ile) to CAC (His), the 225th codon was changed from CCC
(Pro) to AGG (Arg), and the 226th codon was changed from GAT (Asp) to
GAAT (1 bp insertion, Glu) in ACC sample no. 5.
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Discussion
MMM of the head and neck constitute approximately half of
all malignant melanoma cases (22). These melanomas occur
mainly in the upper respiratory tract in 56% and oral cavity
in 44% (23). Within the oral cavity, the commonest site is the
hard palate in up to 80%, followed, in decreasing order of
frequency, by the upper and lower gingiva and mucosa of
buccal. According to the report of Shah et al, MMM of the
head and neck exhibit a far more aggressive behavior than on
the skin (24). They are more prone to metastasis into and
recurrence in regional and distant sites. 
ACC generally developed in the major and minor salivary
glands. Seifert et al reported in the WHO International histo-
logical classification of tumors that ACC is considered to
have aggressive biological characteristics in terms of local
recurrence, perineural spread and late distant metastasis (25).
Among all salivary gland tumors, approximately 40% are
malignant ones, and when the ACC are combined with muco-
epidermoid carcinoma the total amounts to 80% or more.
ACCs occur mainly in the palatine gland in approximately
35% and in the sublingual gland in approximately 30% (26).
ACC has characteristics of a tendency towards permeation
and intensive recurrence, and prognosis is generally poor.
In this study, we have analyzed and examined the molecular
biological characteristics of MMM and ACC, by analyzing
LOH and MSI for allelic imbalance. We carried out investig-
ations to achieve a better understanding of the extent of
alterations affecting chromosomes 1p32, 6q23-25, 9p21,
10q23-25, 11q23.3, 12q12-13, 17p13.1, and 19q13.1. From
the results, LOH at one or more loci was found in 6 of the 12
informative MMM at 50% and 8 of the 15 informative ACC
at 80%. The most frequently deleted region was D9S171 in
the location of the p16/CDKN2 gene on 9p21. The frequency
rate was 33.3% in MMM and 53.3% in ACC. On the other
hand, a 40% level of LOH incidence was detected in the
D12S391 region located in chromosome 12q12-13. Yet, we
focused our attention on microsatellite deletion in this region
in MMM and ACC because the literature does not evidence
any significant presence of TSG in this region. Therefore the
hitherto unreported presence of some as-yet unknown TSGs
cannot be ruled out. Further study is needed to shed light on
this. LOH at a low frequency was detected on D6S310,
D9S162, D9S736, D11S29, D12S1301, D19S210, and
D19S246. However the incidence of LOH in all of these
locations fell short of 20% and it was therefore not justified
to consider them as common deletion domains. In this context,
we are particularly interested in two regions, excluding p16/
CDKN2 which is a microsatellite domain of D9S171. The
two regions are 6q23/25, which is a domain of D6S310, and
p53 which is located at 17p13.1. The reason why these two
regions arouse our particular interest lies in the fact that they do
not exhibit LOH expression. Our research thrust will therefore
concentrate on an analysis of the particular molecular biological
characteristics of the 9p21 and p16/CDKN2 regions. 
The domain of the p16/CDKN2 gene is one of the p16
family, and the p16 gene has a length of 25 kb and is situated
on chromosome 9p21. It has been reported in the earlier
literature to be involved in various cancers (27). One role
played by p16 as a TSG is that the growth suppressing activity
of the retinoblastoma susceptibility gene product, pRb, is
down-regulated by cyclin-dependent kinases 4 and 6 (CDK4
and CDK6) whose activity is negatively regulated by CDK
inhibitors of the p16 family (28,29). The p16 gene may be a
critical target in human carcinomas. Caldas et al reported
that frequent allelic losses were detected in location of the
p16/CDKN2 gene in many types of tumors including breast
cancer, bladder cancer, head and neck cancer, esophageal
SCCs, pancreatic adenocarcinomas and non-small cell lung
carcinomas (30). In particular, Nakanishi et al reported that the
p16/CDKN2 gene is commonly deleted in head and neck SCCs
(53%) (5). These results suggest that a putative suppressor
associated with many cancers is located at this region, but
there have been no reports of p16/CDKN2 gene LOH in both
MMM and ACC of the head and neck. Our attention therefore
focuses on mutation in p16/CDKN2 as a TSG.  
In this study, we have examined somatic mutations of the
p16/CDKN2 gene to determine whether these are associated
with MMM and ACC of the head and neck. Eight somatic
mutations of the p16/CDKN2 gene were detected in 3 patients
(1 MMM and 2 ACCs). These mutations have not been
identified in any other type of tumor (Table V).
Previous studies have reported somatic mutation in exon 2
of p16/CDKN2 (10,31). Mutations have also been reported at
codon 80 in salivary duct carcinomas (10). This finding aroused
our interest. All mutations detected were located within exon 4
of the p16/CDKN2 gene. Interestingly, we found 2 somatic
mutations in the p16/CDKN2 gene in all samples of both
MMM and ACC showing abnormal SSCP patterns, both
mutations were present at codon 225 and codon 226, which
created a truncated p16/CDKN2 gene product. Thus, codon
225 and codon 226 may be mutational hot spots of the
p16/CDKN2 gene in MMM and ACC of the head and neck.
These findings suggest that the p16/CDKN2 gene has another
potential tumor-suppression function, seeing that the mutation
was detected in another domain not previously reported.
However, the functional inactivation of p16/CDKN2 by this
mutation still remains to be clarified. For example, in ACC
sample no. 5, a 1-bp insertion was detected in codon 226,
resulting in a sequence shift after stop codon 227, disrupting
the stop sequence. In order to determine the implications of
this, the sequence following p16/CDKN2 will need to be
further clarified and the functionality of the proteins expressed
confirmed in order to determine the influence of mutation at
exon 4. On the other hand, a number of studies have found a
relation between p16/CDKN2 and the hypermethylation status
of its promoter gene in ACC (32). Therefore, in further study,
we need to identify the protein functionality of p16/CDKN2.
Apart from the three patients mentioned above, none of the
patients showed evidence of mutation, but did reveal mobility
shifts. We concluded that this might be a case of polymorphism.
It is also possible that these mobility shifts resulted from an
artifact occurring during the PCR-SSCP. We used 12-cm
long 10% polyacrylamide gel strips during the process, and
such short strips of gel can not be divided into bands with
PCR-SSCP. This may be a weakness of the study design, and
clarification of this point will require further study using longer
gels.
We will cautiously approach the issue of whether there is
a relation between the effectiveness of HIMAC radiotherapy
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and the biological characteristics of the p16/CDKN2 gene.
As mentioned above, on the one hand, p16/CDKN2 has an
influence on the down-regulation of the cell cycle and, on
the other, HIMAC is characterized by the unique feature that
its radiation is effective on cells regardless of cell status
and of the cell cycle. No analytical procedure for assessing
the molecular biological effects of HIMAC radiation has
been established yet. However, the discovery of p16/CDKN2
mutations different from those of earlier literature publications
might suggest the possibility of some relation between the
effect of the HIMAC and these mutations.
Further studies are needed to clarify the role of the p16/
CDKN2 gene in the development and progression of MMMs
and ACCs of the head and neck.
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